IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, 40138, Italy
Location status: Recruiting
NCT Number: NCT06728007
A retrospective, observational multicentre trial on the nephrological outcome and associated congenital anomalies in children with Horseshoe Kidney.
Interested in participating?
Request InfoUp to 18 year
All sexes
Observational
Bologna, 40138, Italy
Location status: Recruiting
Congenital abnormalities of the kidney and urinary tract (CAKUT) represent the main cause of CKD in children. Among them, the horseshoe kidney (HSK) represents one of the most frequent and is characterised by the presence of two distinct, functioning kidneys positioned on each side of the spine, fused together at one of the poles. The incidence of this condition is approximately 1 case every 400-600 new births with a prevalence in the male sex with a ratio of 2:1. Even though these children aregenerally asymptomatic and the diagnosis is often incidental , some may develop symptoms due to complications, such as infections, nephrolithiasis and urinary tract obstruction. More rarely risks of neoplastic degeneration and renal damage are described following trauma to the abdomen and lumbosacral spine. This condition is also associated in up to a third of cases with other abnormalities: the most frequent affect the urinary tract and genitals; however, abnormalities affecting other organs or systems as well as well-defined syndromic pictures. Due to its frequent asymptomatic nature, horseshoe kidney is historically considered a condition with a good prognosis and rarely as a risk factor capable of reducing survival or predisposing the kidney to long-term damage.
The primary objective of the study is:
To assess the 'nephrological outcome' understood as 'prevalence of patients who developed' and 'survival time free from": chronic renal failure, proteinuria, hypertension nephrolithiasis, UTI, renal neoplasms and renal trauma.
The secondary objectives of the study are:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: at baseline
Defined as a reduction in eGFR <90ml/min/1.73m2, calculated using the Schwartz formula(18) corrected for age:
The different stages of chronic kidney have been further defined according to eGFR:
Time frame: at baseline
Defined as the urinary protein:creatinine ratio (mg/mg) >0.5 in chilrden up to 2 yrs of age and >0.2 in chilrden older than 2 yrs
Time frame: at baseline
Arterial blood pressure ≥95th percentile for sex, age and height, on at least three different readings
Time frame: at baseline
Confirmed by urine analysis and urine culture in a compatible clinical picture
Time frame: at baseline
Documented finding by imaging techniques (ultrasound and/or CT) of formations compatible with lithiasis formation
Time frame: at baseline
Diagnosis confirmed by imaging and histology of the neoplasm of renal origin (especially Wilms' tumour)
Time frame: at baseline
Renal length measured as bipolar diameter with renal hypoplasia defined as the presence of kidneys with DBP <5° centile reference for age and height
Time frame: at baseline
Ultrasound description of abnormalities of the renal parenchyma with renal dysplasia defined by the presence of alterations such as: hyperechogenicity, reduced cortico-middular differentiation, reduced cortical thickness due to age, presence of multiple cystic formations
Time frame: at baseline
Presence of instrumentally documented renal lesions (ultrasound and/or CT scan) following a traumatic episode
Contact information is provided by the study sponsor or research team.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001595
Acromegaly, Adenoma
Bethesda, Maryland, United States
View Trial DetailsNCT04717349
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Bethesda, Maryland, United States
View Trial DetailsNCT07431112
Alpha 1 Antitrypsin Deficiency, Congenital Abnormalities
Melbourne, Australia
View Trial DetailsNCT07654114
Central Nervous System Diseases, Chromosome Disorders
Barcelona, Spain
View Trial Details